Dr. Michael Gallatin joined Frazier Healthcare Ventures in 2006 as Venture Partner to the Biopharma team. Previously, Dr. Gallatin was Vice President and Scientific Director of ICOS corporation, a significant public biopharma company. Dr. Gallatin's management responsibilities at ICOS included discovery, preclinical research, medchem and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Dr. Gallatin is currently President of Calistoga Pharmaceuticals, a Frazier Healthcare portfolio company. He is also currently a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, BioSeek, and the University Of Texas Department Of Chemistry and is a member of the BioSeek Board of Directors.

Dr. Gallatin received his Ph.D. in 1981 from the University of Alberta Department of Immunology. Dr. Gallatin's doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman, Dr. Gallatin discovered the first cell adhesion molecule implicated in site selective leukocyte traffic. Dr. Gallatin continued his research in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center prior to his recruitment by Drs. Chris Henney and George Rathmann as one of the founding scientists at ICOS corporation in 1990.

Feel free to contact him at michael@frazierhealthcare.com